Dianthus Therapeutics (DNTH) Long-Term Investments (2024 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Long-Term Investments of $110.1 million for Q4 2025, up 34.76% year-over-year from $81.7 million in Q4 2024, and down 27.96% quarter-over-quarter from $152.9 million in Q3 2025.
Powered by 
Analysis
Dianthus Therapeutics (DNTH) Long-Term Investments (2024 - 2025) Analysis & Trends
Dianthus Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $110.1 million for Q4 2025.
- In Q4 2025, Long-Term Investments rose 34.76% year-over-year to $110.1 million; the TTM figure through Dec 2025 stood at $110.1 million (up 34.76% YoY), while the FY2025 annual figure was $110.1 million, up 34.76% from the prior year.
- Long-Term Investments for Q4 2025 stood at $110.1 million, down from $152.9 million in the prior quarter.
- The five-year high for Long-Term Investments was $152.9 million in Q3 2025, with the low at $51.7 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Dianthus Therapeutics | 4.09 Bn | 3.69 Bn | - | 110.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 110.14 Mn |
| Sep 30, 2025 | 152.87 Mn |
| Jun 30, 2025 | 51.71 Mn |
| Mar 31, 2025 | 68.31 Mn |
| Dec 31, 2024 | 81.73 Mn |
| Sep 30, 2024 | 61.48 Mn |